Heineken Hires GLP-1 Endorser to Address Declining U.S. Alcohol Consumption
U.S. consumption of alcoholic beverages is at historic lows, according to a recent Gallup poll and industry reports. In response, Heineken has appointed Serena Williams as the global ambassador for its non-alcoholic beer line while she also promotes GLP-1 weight-loss drugs linked by investors to reduced alcohol demand. The move highlights broader challenges in the U.S. beer market, where companies like Boston Beer (SAM) and Molson Coors (TAP) have seen declining sales volumes and share prices over recent quarters. Boston Beer reported a 24% miss on Q2 earnings with depletions down 6%, while Molson Coors saw US shipments fall by 7%. Both companies are struggling to offset the broader industry contraction, which declined by 4% in the quarter. Molson Coors is diversifying into non-beer products through acquisitions like Monaco Cocktails and partnerships such as Fever-Tree. Heineken's CEO acknowledged uncertainty around GLP-1s' impact on drinking habits but emphasized that studies show people using these drugs still consume alcohol, albeit with inconclusive effects. Analysts suggest the industry faces a chronic 1–2% annual decline in per capita consumption due to health concerns and shifting consumer preferences.
Topics: alcohol consumption beer industry decline executive interviews GLP-1 drugs M&A activity